In healthcare technology, Israel and the UK are complementary markets – and together, they are perfectly placed to make a difference in the global healthtech space.
Israel's population of less than 10 million people effectively dictates that health technology companies explore global markets at an early stage. From trialling and testing to adoption and scale, Israeli technology companies look for overseas markets with low friction and high expansion potential.
The UK is well-placed to serve as a first international port of call. Thanks to its large population and user base open to new technologies, highly advanced health technology market, and agreeable linguistic, financial and proximity factors, the UK is the ideal springboard for Israeli companies to launch into the global health technology market.
Israel’s public healthcare system has proven to be a nimble ecosystem for product piloting and trials. Its relatively small population, however, means that the opportunity for product scale in Israel is very limited, necessitating early-stage global market penetration. As the UK leaves the EU and explores opportunities for inward investment flows and innovative, global companies to grow in Britain, the Israeli healthtech sector is a still largely untapped ecosystem.
Taylor Wessing is proud to be part of this exciting new chapter in UK-Israeli healthtech collaboration, as the sponsors of the UK Israel Healthtech Forum 2021. The Forum connects leading UK health professionals, NHS technology and innovation leaders, academic health networks and local investors with Israel’s top healthtech leaders and companies.
This year, the Forum will kick off with the unveiling of A shot in the arm: Israel-UK Healthtech Innovation, a report which highlights the burgeoning collaboration between the two health innovation powerhouses. Written in collaboration with the All-Party Britain-Israel Parliamentary Group, the report will go live at a virtual launch event attended by members of Parliament and The House of Lords.